Cabaletta Bio, Inc. (CABA)

NMS – Real Time Price. Currency in USD

3.63

-0.19 (-4.97%)

At close: May 12, 2026, 4:00 PM EDT

3.80

+0.17 (4.68%)

Pre-market: May 13, 2026, 4:02 AM EDT

04.05.2026

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million. The offering is expected to close on or about May 5, 2026, subject to the satisfaction of customary closing conditions. The financing included participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management and other existing investors, multiple new mutual and sovereign wealth funds and Eli Lilly and Company.

28.04.2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (Nasdaq: CABA) for the automated manufacture of rese-cel (resecabtagene autoleucel), Cabaletta's investigational CAR T cell therapy for autoimmune diseases. The agreement secures the long-term manufacturing capacity and supply predictability required to address the global.

28.04.2026

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial translational data from the first two patients dosed with rese-cel manufactured by Cellares will be presented at the ASGCT conference in May PHILADELPHIA and SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a commercial agreement to supply rese-cel (resecabtagene autoleucel) using Cellares' automated Cell Shuttle and through future implementation of Cellares' Cell Q platform.

27.04.2026

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced multiple upcoming presentations including manufacturing, translational and clinical data on rese-cel (resecabtagene autoleucel) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held from May 11-15, 2026, in Boston, MA.

14.04.2026

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or “Cabaletta”) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle™ automated manufacturing platform. The administration of an autologous cell therapy, which met all release.

23.03.2026

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option

06.03.2026

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Videos

No Data

There is no data to display

Press releases

04.05.2026

Cabaletta Bio, Inc. (CABA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Videos

No Data

Press releases

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Videos

No Data

Press releases

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Search stocks

Cabaletta Bio, Inc. (CABA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cabaletta Bio, Inc. (CABA)

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Videos

No Data

Press releases

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Videos

No Data

Press releases

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting